Metraipolis › archive › dc_deae217c080c

CT-based immune radiomic signature for prognosis and prediction of immunotherapy and anticancer drug response in NSCLC — Europe PMC PMID:42136648

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42136648
DOI: 10.3389/fimmu.2026.1767389
License (as archived): solo-consultazione
Archived: 2026-11-03T01:37:29.450Z
SHA-256 of the archived text: 5ef9ff4213174a420d398356f3ffe360618e8ce707d7f4893c319067d62e1693
Stable URL of this page: https://metraipolis.com/documento/dc_deae217c080c

How to cite

CT-based immune radiomic signature for prognosis and prediction of immunotherapy and anticancer drug response in NSCLC — Europe PMC PMID:42136648 — Europe PMC (en), https://europepmc.org/article/MED/42136648 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_deae217c080c (Metraipolis archive dc_deae217c080c, sha256 5ef9ff4213174a420d398356f3ffe360618e8ce707d7f4893c319067d62e1693)

BibTeX

@misc{dcdeae217c080c,
  title = {CT-based immune radiomic signature for prognosis and prediction of immunotherapy and anticancer drug response in NSCLC — Europe PMC PMID:42136648},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42136648},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_deae217c080c; sha256 5ef9ff4213174a420d398356f3ffe360618e8ce707d7f4893c319067d62e1693},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42136648. Agents can read the archived copy with the MCP tool read_document.